In a recent post in the New York Times “Economix” blog, titled “The Dollar Value of an Extra Year of Life,” Professor Uwe E. Reinhardt of Princeton uses the March 2014 California Technology Assessment Forum (CTAF) meeting on Hepatitis C to explore the numerous issues that arise when society is faced with how to pay for a new, high-priced, effective drug. CTAF is a core program of ICER.
